| 发明名称 | Anti-AREG/HB-EGF antibodies and treatment | ||
| 摘要 | Described are cross-specific antibody molecules with binding specificity for both AREG and HBEGF. The antibody molecules may be used in methods of treatment of cancer and diseases associated with angiogenesis. | ||
| 申请公布号 | US8846868(B2) | 申请公布日期 | 2014.09.30 |
| 申请号 | US200912988135 | 申请日期 | 2009.04.17 |
| 申请人 | Fusion Antibodies Limited | 发明人 | Caswell Jill;Olwill Shane;Johnston James;Buick Richard;Jaquin Thomas;Doherty Declan;Scott Christopher |
| 分类号 | C07K16/00;C12P21/08;C07K16/22;A61K39/395;C07K16/28;A61K39/00 | 主分类号 | C07K16/00 |
| 代理机构 | Drinker, Biddle & Reath, LLP | 代理人 | Drinker, Biddle & Reath, LLP |
| 主权项 | 1. An isolated antibody molecule which binds HBEGF and AREG and inhibits the activity of HBEGF and the activity of AREG, wherein the antibody molecule comprises the three CDRs of the VH sequence shown as SEQ ID NO:7 and the three CDRs of the VL sequence shown as SEQ ID NO:8. | ||
| 地址 | Belfast GB | ||